Zurich Cantonal Bank
JUNO

Zurich Cantonal Bank’s Juno Therapeutics, Inc. JUNO Stock Holding History

Zurich Cantonal Bank’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-17,196
Closed -$786K – 2566
2017
Q4 		$786K Buy
17,196
+1,404
+9% +$70K 0.01% 813
2017
Q3 		$708K Buy
15,792
+12,421
+368% +$423K 0.01% 823
2017
Q2 		$101K Sell
3,371
-10,514
-76% -$259K ﹤0.01% 1370
2017
Q1 		$308K Sell
13,885
-799
-5% -$17.1K ﹤0.01% 913
2016
Q4 		$277K Sell
14,684
-121,311
-89% -$2.97M ﹤0.01% 922
2016
Q3 		$4.08M Buy
135,995
+1,146
+0.8% +$35.7K 0.04% 442
2016
Q2 		$5.18M Buy
134,849
+4,062
+3% +$169K 0.07% 313
2016
Q1 		$4.98M Buy
130,787
+554
+0.4% +$19.3K 0.06% 317
2015
Q4 		$5.73M Buy
130,233
+6,872
+6% +$341K 0.07% 273
2015
Q3 		$5.02M Buy
123,361
+114,722
+1,328% +$5.03M 0.07% 262
2015
Q2 		$461K Buy
8,639
+2,739
+46% +$145K 0.01% 860
2015
Q1 		$358K Buy
+5,900
New +$286K 0.01% 870

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Zurich Cantonal Bank's JUNO Position: Q1 2018 in Review

Zurich Cantonal Bank sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 17,196 shares — an estimated $786K sold.

Zurich Cantonal Bank first reported a position in JUNO in Q1 2015 and held it in 12 quarters. The position peaked at $5.73M in Q4 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Zurich Cantonal Bank reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Zurich Cantonal Bank sold 17,196 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $786K.
  • Zurich Cantonal Bank first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 12 quarters.
  • Zurich Cantonal Bank's Juno Therapeutics, Inc. position peaked at $5.73M in Q4 2015.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Zurich Cantonal Bank's 13F filing for Q1 2018, filed 3 May 2018.